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GreecePurpose. The aim of this article is to discuss the role of inflammation in atherosclerosis.
Summary. An initial chemical, mechanical or immunological insult induces endothelial dysfunction. This triggers a
cascade of inflammatory reactions, in which monocytes, macrophages, T lymphocytes and vascular smooth muscle cells
participate. Leukocyte adhesion molecules, cytokines, growth factors and metalloproteinases participate in all stages of
atherogenesis. Almost all of the traditional risk factors for atherosclerosis are associated with and participate in the
inflammatory process. Many infectious agents, mainly Chlamydia pneumoniae, have been proposed as potential triggers
of the cascade. The immune system has been implicated in plaque formation, through the activation of cellular and humoral
immunity against innate or microbial heat shock protein 60. Methods of detection of systemic or local plaque inflammation
have been developed and research is being conducted on the potential use of anti-inflammatory and antibiotic drugs in
atherosclerosis.Keywords: Inflammation; Infection; Atherosclerosis; Endothelium; Risk factors; Plaque evolution.Introduction
Almost 200 years ago London surgeon J. Hodgson
observed the inflammatory characteristics of athero-
sclerotic lesions.1 A causative role of inflammation and
infection in the pathogenesis of atherosclerosis was
first proposed in 1908 by Sir William Osler.2 For the
major part of the 20th Century, the lipid theory
dominated the field of atherogenesis. R. Ross reopened
the discussion on the inflammatory nature of athero-
sclerosis some 30 years ago, with his first significant
review on atherosclerotic plaque formation.3
The response-to-injury theory of atherogenesis, is
still valid with minor alterations. Endothelial dysfunc-
tion seems to be the first step in atherogenesis. From
this point on, an inflammatory response is triggered
that leads to the development of atherosclerotic
plaque.4 This review summarizes the experimental
and clinical evidence that links inflammation to
atherosclerosis.ing author. Elias A. Kaperonis, MD, 85, G. Zografou
hens, Greece.
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It has been established in the last 15 years, that the
endothelium is not a simple lining of cells on the inner
arterial wall. Endothelial cells secrete a wide variety of
active molecules5 (Fig. 1). Healthy endothelium is an
important barrier to the free passage of molecules and
cells to the underlying interstitium and a dynamic
endocrine organ, which not only mediates endo-
thelium-dependent vasodilation, but also actively
inhibits leukocyte adhesion and migration, platelet
adhesion and aggregation and vascular smooth
muscle cell proliferation and migration. It also inhibits
coagulation, promotes fibrinolysis and participates
actively in immune and inflammatory reactions.6
Endothelial dysfunction or activation can occur in
response to a variety of stimuli such as oxidized LDL,
free radicals caused by smoking, hypertension,
diabetes, genetic alterations, elevated plasma homo-
cysteine concentrations and infectious microorgan-
isms. Endothelial homeostasis is disturbed and this
affects permeability, vasoconstriction, coagulation andEur J Vasc Endovasc Surg 31, 386–393 (2006)
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Fig. 1. The endocrine nature of the endothelium: endothelial
cells are mini factories that produce a large variety of
important substances, that control vasomotor activity (nitric
oxide, endothelin and leukotrienes), coagulation (thrombo-
plastin, thromboxane A2, von Willebrand factor, factor V,
platelet activating factor, plasminogen activator inhibitor,
heparin, anti-thrombin, thrombomodulin, prostacyclin, plas-
minogen activator), vascular inflammation (interleukins,
cytokines), extracellular matrix production (fibronectin,
collagen, proteoglycanes) and cell hypertrophy (insulin like
growth factor, colony stimulating factor).
Inflammation and Atherosclerosis 387triggers inflammatory and immunologic reactions. It
has been demonstrated that endothelial dysfunction is
one of the earliest signs of atherosclerosis, even in the
absence of angiographic evidence of disease. Reduced
nitric oxide (NO) activity is one of the earliest and
more important markers of endothelial dysfunction.7
Endothelin-1 (ET-1), a vasoconstrictor, seems to be in a
sensitive balance with NO regulating vascular tone. It
has been shown that ET-1 may be involved in
atherosclerosis8 and that ET receptors have an
increased expression in human atherosclerotic pla-
ques.9 If the inflammatory response fails to neutralize
the offender, the inflammation goes on and stimulates
migration and proliferation of smooth muscle cells.
The response is mediated by monocyte-derived
macrophages and specific subtypes of T-lymphocytes.
Excessive inflammatory and fibroproliferative
responses lead to thickening of the arterial wall and
the formation of the atherosclerotic lesion.Inflammation in the Initiation of Atherosclerosis
Healthy endothelium, does not normally bind white
blood cells. Soon after atherogenic diet is initiated,
many endothelial cells begin to express on their
surface adhesion molecules (selectins, intercellular
adhesion molecules ICAMs, vascular cell adhesion
molecule VCAMs) that act as receptors for glycocon-
jugates and integrins present on monocytes and
T-cells. In particular VCAM-1, binds precisely the
types of leukocytes found in early human and
experimental atheroma, the monocyte and the T
lymphocyte. Mice genetically engineered to express
defective VCAM-1, show interrupted lesion
development.10Defective atheroprotective mechanisms, could also
contribute to the initiation of atherosclerosis. At
branch points of the arterial tree, the absence of
normal shear stress reduces local production of
endothelium-derived NO,11 which can block the
expression of VCAM-1.12 Turbulence and abnormal
shear stress, can increase the production of ICAM-1,13
and promote the production by arterial smoothmuscle
cells of proteoglycans, which can bind and retain
lipoprotein particles, which after their oxidation
promote an inflammatory response at sites of plaque
formation.14
After their attachment to the arterial wall, leuko-
cytes begin their migration into the intima, with the
help of several chemoattractant molecules. Monocyte
chemoattractant protein-1 (MCP-1) appears to be
responsible for the migration of monocytes into the
intima. Another class of T cell chemoattractants helps
lymphocytes penetrate the inner arterial wall.15 Once
inside the intima, monocytes are converted into
macrophages and start to express on their surface,
scavenger receptors for modified lipoproteins, under
the influence of macrophage-colony stimulating factor
(M-CSF).16 M-CSF leads to the ingestion of lipids, and
to the multiplication and differentiation of monocytes
into macrophage foam cells. This characteristic lesion
which consists of macrophage foam cells and T-cells,
situated under a monolayer of endothelial cells, is the
first lesion of atherosclerosis, the so called fatty-streak.Inflammatory Evolution of Atherosclerosis
In the fatty-streak lesion, T-cells are activated and
together with native vascular wall cells, secrete
cytokines (tumor necrosis factor-b, g-interferon),
fibrogenic mediators and growth factors that can
promote the migration and proliferation of smooth
muscle cells (SMC) and the construction of a dense
extracellular matrix around them, characteristic of an
advanced atherosclerotic lesion. Medial SMCs express
specialized enzymes that can degrade the elastin and
collagen in response to inflammatory stimulation. This
degradation of the arterial extracellular matrix permits
the penetration of the SMCs through the internal
elastic laminae and their migration to the subintimal
area.4 At the same time SMCs secrete factors that
recruit additional monocytes.17
The macrophage-lipid component of the plaque,
T-lymphocytes and the fibromuscular component
(SMCs and extracellular matrix), enter a vicious cycle
of cell migration to the subintimal area, cell prolifer-
ation and overproduction of fibrous tissue, leading to
intimal thickening, intermediate lesions andEur J Vasc Endovasc Surg Vol 31, April 2006
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Fig. 2. Inflammatory cells (monocytes, T-cells) and proinflammatory mediators (cytokines, interleukins) have a key role in the
initial phase and progression of atheroma formation. Repeated cycles of intimal thickening lead from the first lesion of
atherosclerosis, the fatty streak, to intermediate and advanced lesions.
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of activated cells release proinflammatory mediators.
Inflammatory cytokines, including IL-1, tumor necro-
sis factor (TNF) and CRP induce the expression of
cellular adhesion molecules, which mediate adhesion
of the leukocytes to the endothelium.18 Gradually, the
so called advanced atherosclerotic lesion is formed,
with the characteristic core of lipids and necrotic tissue
which is covered by a fibrous cap. The necrotic core is
formed from the apoptosis and necrosis of macro-
phages, which empty their lipid contents inside the
plaque. The fibrous cap, is probably formed by
migration of typical contractile vascular SMCs from
the media, which accounts for the frequent medial
wasting observed at the base of atherosclerotic
plaques19 and from collagen produced by the SMCs.Involvement of Inflammation in Plaque Destabili-
zation and Atherothrombotic Complications
Myocardial infarction (MI), fatal coronary thrombosis
and stroke are the main consequences of either
catastrophic rupture or surface erosion of the fibrous
cap. Rupture is responsible for 80% of fatal MI in men.
It occurs in regions of high tangential stress and
collagen depletion.20 Plaque erosion accounts for 50%
of MI in young women.20 In a quarter of cases, plaque
does not rupture. The endothelium is simply replaced
by the prothrombotic inflammatory cells.21 Stable
advanced lesions usually have uniformly dense
fibrous caps. At autopsy, plaque rupture usually
occurs in areas of sustained inflammation,Eur J Vasc Endovasc Surg Vol 31, April 2006macrophage accumulation and apoptosis,22 often at
the shoulders of the lesion.
Activated T-cells may stimulate MMP production
by macrophages in the lesion.23 The activated macro-
phage, produces these proteolytic enzymes, capable of
degrading the collagen of the plaque’s protective
fibrous cap, rendering it susceptible to rupture.
Activated T lymphocytes, produce g-interferon that
can halt collagen synthesis by the SMCs, limiting its
capacity to renew the collagen that reinforces the
cap.24 The potentially dangerous lesions are often non-
occlusive and thus difficult to diagnose by angiogra-
phy. On histopathological examination, active inflam-
mation is evident in these lesions. Half of all
infarctions occur in arteries that have !50% luminal
stenosis, that is generally considered a stenosis
hemodynamically insignificant.25 However, the
presence of inflammation seems to be the key event.
Plaque inflammation may be associated with
increased plasma concentrations of both fibrinogen
and CRP.26Inflammation and Traditional Risk Factors of
Atherosclerosis
Low density lipoproteins (LDLs) and especially their
modified forms (oxLDL, glycLDL, etc.), have a
deleterious effect on the endothelium and the under-
lying smooth muscle. Once LDLs are trapped in the
intima, they undergo oxidative modification. These
modified lipids can induce the expression of adhesion
molecules, proinflammatory cytokines and other
Inflammation and Atherosclerosis 389mediators of inflammation in macrophages and
endothelial cells. They are taken up by the macro-
phages and finally they are found in the necrotic core
of the advanced lesion, after the apoptosis of the
macrophages. Despite the abundant evidence support-
ing the importance of LDL oxidation in human
atherosclerosis, anti-oxidant (b-carotene, vitamin C
and vitamin E) therapy has not been shown to reduce
cardiovascular event rate in clinical trials.27
Very low-density lipoproteins (VLDL) and inter-
mediate density lipoproteins (IDL), can undergo
oxidation just like LDL and some evidence even
suggest that beta VLDL can activate inflammatory
functions of vascular endothelial cells.28 The ather-
oprotective effect of high-density lipoprotein (HDL)
may in part result from its anti-inflammatory and anti-
oxidant properties. HDL particles can carry anti-
oxidant enzymes, such as platelet-activating factor,
acetylhydrolase and paraoxonase, which breakdown
oxidized lipids and neutralize their proinflammatory
effects. Surprisingly, HDL isolated from coronary
artery disease patients without diabetes and with
average lipid levels, did not protect LDL from
oxidation.29
Sphingosine kinase (SphK), an enzyme responsible
for the conversion of sphingosine to sphingosine-1
phosphate, has emerged in recent years as an
important link between lipid metabolism and inflam-
mation in the arterial wall. The SphK pathway,
responsible for the expression of adhesion molecules
and cell proliferation of human SMC,30 seems to be
activated by cytokines and ox-LDL and inhibited by
HDL.31 Finally, there is now a considerable amount of
evidence, that statins, the cornerstone of lipid low-
ering therapy, also have anti-inflammatory proper-
ties,32 and part of their effect on cardiovascular
mortality and morbidity is due to their anti-inflam-
matory action.
Hypertension is one of the classical risk factors for
atherosclerosis. Angiotensin II (AII), the principal
product of the renin-angiotensin system and a potent
vasoconstrictor, increases protein synthesis and
smooth muscle hypertrophy.33 It also increases smooth
muscle lipoxygenase activity, which in turn increases
inflammation and LDL oxidation. AII augments the
formation of hydrogen peroxide and free radicals such
as superoxide anion and hydroxyl radicals in
plasma.34 These oxidative inflammatory products
block the formation of nitric oxide by the endothelium,
increase leukocyte adhesion and peripheral resistance.
Arterial SMCs treated with AII demonstrate increased
expression of proinflammatory cytokines such as IL-6
and monocyte chemoattracting protein-1 (MCP-1),
while endothelial cells show increased expression ofthe adhesion molecule VCAM-1.35 By interrupting the
expression of adhesion molecules and cytokines,
angiotensin-converting enzyme inhibitors (ACEI)
exert anti-inflammatory effects on the development
of atherosclerosis. The protective effect of Angiotensin
II blockade goes over and beyond its anti-hypertensive
action.36
Five major molecular mechanisms have been
implicated in hyperglycemia induced endothelial
damage: activation of protein kinase C isoforms via
de novo synthesis of the lipid second messenger
diacylglycerol, increased hexosamine pathway flux,
increased advanced glycation end product (AGE)
formation, increased polyol pathway flux and acti-
vation of the proinflammatory nuclear transcription
factor nuclear factor-kappa B.37 In an effort to evaluate
diabetes-induced oxidative stress and inflammation, it
has been documented that there is an increased
cytokines, chemokines and adhesive molecules pro-
duction in the arterial wall of streptozotocin-induced
diabetic swine.38 Oxidative stress was responsible for
this inflammatory response mediated by AGE-
induced activation of the transcriptional factor nuclear
factor-kappa B in coronary adventitial fibroblasts
providing a mechanistic link between diabetes,
oxidative stress and inflammation. Inflammation can
also extend into the tunica media, inducing atrophy
and fibrosis. Increased content of macrophage-derived
MMP-2 and -9 within the intima-media interface of
advanced plaques has been described. This increased
activity of MMP is associated with disruption of the
internal elastic lamina, an independent predictor of
plaque rupture.39 Plaque composition may be different
in patients with diabetes. Macrophage infiltration and
thrombus formation are increased in advanced coron-
ary plaques from diabetic patients with unstable
angina.40
Adipose tissue can synthesize cytokines such as
TNF-a and IL-641 and in this way obesity can promote
inflammation and advance atherogenesis, indepen-
dently of its effects on insulin resistance and lipopro-
tein metabolism. Peroxisome proliferators-activated
receptors (PPARs) are lipid-activated nuclear
receptors that serve as transcriptional regulators of
genes encoding for proteins involved in glucose and
lipid metabolism. In obese insulin-resistant mice, diet
restriction caused a 45% weight loss, an upregulation
of PPAR-alpha and PPAR-gamma and a change in the
expression of genes regulating glucose transport and
insulin sensitivity, lipid metabolism, oxidative stress,
and inflammation, most of which are under the
transcriptional control of these PPARs.42 It has also
been shown, that in overweight men, low fat and very
low carbohydrate diet, results in significant decreasesEur J Vasc Endovasc Surg Vol 31, April 2006
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ICAM-1.43 In another study, MCP-1 production in
isolated adipocytes, was reduced after weight loss in
morbid obese subjects.44 Therefore, it seems that there
is an association between obesity and in particular
visceral obesity and low grade inflammation.45
There is increasing evidence that major dietary
patterns are associated with markers of inflammation
and endothelial dysfunction. In a recent study,
spontaneously hypertensive rats were fed broccoli
sprouts, whose ingredient glucoraphanin has been
shown to reduce oxidative stress. This diet decreased
NF-kB activation, which resulted in decreased tissue
infiltration of activated macrophages46 and reduced
blood pressure. In a non-human primate model,
ovariectomized monkeys on a moderately atherogenic
diet plus soy isoflavones or conjugated equine
estrogens, were studied at the end of a 3-year period.
Both isoflavones and equine estrogens reduced
VCAM-1, but only estrogens reduced MCP-1.47
Postmenopausal women at risk for coronary artery
disease, were placed on a rigorous high-fiber low-fat
diet and on a regular exercise intervention program.
This intervention not only improved their metabolic
and lipid profiles, but also reduced the levels of
inflammatory (CRP, SAA) and adhesion (ICAM-1)
molecules without caloric restriction.48 In a very
important recent study, two types of diet were
compared: the rich in fiber and white meat Mediterra-
nean diet and the rich in saturated fat, carbohydrates
and red meat Western diet. Mediterranean diet was
inversely associated with CRP and E-selectin plasma
concentrations, whereas Western diet was correlated
with CRP, interleukin-6, E-selectin, ICAM-1 and
VCAM-1 levels,49 significant markers of inflammation
and endothelial dysfunction.Inflammation and Infection
In the light of the importance that inflammation has
assumed in the recent years in the process of
atherogenesis, many have suspected that an infectious
agent could be behind chronic inflammation of
atheroma. Both bacteria and viruses have been
implicated. In vitro CMV infection of macrophages,
increases secretion of IL-1, TNF-a and macrophage
colony stimulating factor (MCSF).50 Indeed it seems
that CMV infection is more important for cardiovas-
cular risk, when it elicits a persistent inflammatory
response, evidenced by high CRP values.51
Escherichia coli endotoxin regulates IL-1 and TNF-a
production in endothelial and vascular smooth muscle
cells.52 Cytokines produced by endotoxin activatedEur J Vasc Endovasc Surg Vol 31, April 2006cells, induce the expression of soluble adhesion
molecules P-selectin, ICAM-1 and VCAM-1 in endo-
thelial cells. Helicobacter pylori has been associated
with coronary events in the West of Scotland study
cohort.53
Chlamydia pneumoniae has been isolated from
atherosclerotic plaques from almost all the sites of
the arterial tree and has also been associated with the
severity of the lesions and with acute clinical
syndromes.54 In chronic chlamydial infections, heat
shock protein (Hsp) 60 is overproduced. It is also
traced on the atheroma and it induces the expression
of adhesion molecules55 and the oxidation of LDL.
Recently, there has been an effort to attribute plaque
inflammation not to one but to multiple pathogens.
This was termed ‘pathogen burden’ and it seems to
have a stronger association with endothelial dysfunc-
tion, inflammation of the lesion and cardiovascular
event rate.56Inflammation and the Immune System
Inflammation of atheromatous lesions could result
from an exaggerated immune response. In basic
defense mechanisms, expression of scavenger
receptors (SR) and toll-like receptors (TLR), are
increased in monocytes and macrophages. SR induce
endocytosis whereas TLR activate transcription
factors, such as NF-kB. Activated NF-kB induces
expression of genes that increase production of
chemoattractant molecules, adhesion molecules, cyto-
kines and reactive oxygen species.57
The more sophisticated adaptive immune response
consists of macrophage presentation of the antigen to
the T lymphocytes. Activated T lymphocytes, attack
the antigen, stimulate B lymphocytes to secrete
antibodies and enhance inflammation by releasing
cytokines (TNF-a, INF-g, IL-1). Cytokines induce
production of chemoattractant molecules including
MCP-1. Genetically modified mice lacking MCP-1 or
its receptor, demonstrate a slower development of
atheromas despite high lipid diet.58
Although the antigens serving as immune targets
in atheroma are unknown, heat shock protein is a
most likely candidate. Some authors have suggested,
that while originally HSPs are intercellular proteins,
marked stress-induced over expression may lead to
their presentation on the cell surface, stimulating an
autoimmune reaction and thereby contributing to the
development of atherosclerosis. This conception of
autoimmune atherogenesis, was strongly supported
by the facts that increased expression of human
Hsp60 has been observed in endothelial cells,
Novel methods of diagnosis of atherosclerosis-related inflammation 
Systemic inflammation Local plaque inflammation
Inflammatory markers (mainly CRP) Temperature heterogeneity pH  heterogeneity
Fig. 3. Diagnostic methods of local and systemic inflammation in atherosclerosis. Many serum inflammatory markers have
been implicated in atherogenesis. On the other hand, only quite recently temperature and pH of the plaque have been
associated to local inflammation and clinical events. Inflammation as we know increases temperature and reduces pH.
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plaques and that anti-human Hsp60 antibodies
correlate with both the presence and the extent of
coronary artery disease.59The Future
Various inflammatory mediators, including adhesion
molecules, cytokines, chemoattractant and growth
factors, have been shown to have distinct roles in the
inflammation of atheroma.60 In the last few years,
there has been an increasing interest in specific serum
markers that could reflect the severity of systemic
inflammation. CRP, serum amyloid A (SAA), proin-
flammatory cytokines and adhesion molecules have
all been linked to increased risk of future cardiovas-
cular events, but the association was strongest for CRP.
TNF-a and IL-6 have been found to be associated with
1-year mortality in critical limb ischemia patients.61
New techniques have been devised in order to detect
local inflammation in the plaque, by measuring
temperature and pH heterogeneity62 based on the
rationale that inflammation increases temperature and
reduces pH (Fig. 3).
The next step would be to treat inflammation and
determine if there is any benefit in cardiovascular risk.
Statins and ACE inhibitors have already shown, that
besides their main action they also have anti-
inflammatory properties and this is reflected on their
impact on cardiovascular mortality. Old (aspirin) and
new (COX-2 inhibitors, PPAR-g agonists) anti-inflam-
matory drugs, are being increasingly used in studies in
patients with vascular disease and the first evidence
has been encouraging.62 Unfortunately, the latest
results have shown that more than one COX-2
inhibitors, are associated with an increased cardiovas-
cular risk.63 Also large antibiotic trials have shown no
reduction in the rate of cardiovascular events.64Conclusions
In the years to come, specific markers and anti-
inflammatory agents may be used in everyday routine
diagnosis and management of vascular disease.
Results of experimental anti-inflammatory medication
in cardiovascular disease, may further support the
clinical importance of inflammation.References
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